The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Open accessAbstract
Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously shown to be due to target-based mutations. Here we report that non-target based resistance to BDQ, and cross-resistance to clofazimine (CFZ), is due to mutations in Rv0678, a transcriptional repressor of the genes encoding the MmpS5-MmpL5 efflux pump. Efflux-based resistance was identified in paired isolates from patients treated with BDQ, as well as in mice, in which it was confirmed to decrease bactericidal efficacy. The efflux inhibitors verapamil and reserpine decreased the minimum inhibitory concentrations of BDQ and CFZ in vitro, but verapamil failed to increase the bactericidal effect of BDQ in mice and was unable to reverse efflux-based resistance in vivo. Cross-resistance between BDQ and CFZ may have important clinical implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 2×
“BK12 BDQ-R mutant, H37Rv-derived, atpE mutation [2] no mutation no mutation 2.”
BackgroundSelf-citationPalomino, J.-C., Martin, A., Camacho, M., Guerra, H., Swings, J., & Portaels, F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2720-2722.2002 · Cited by 1,229
Diarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
Self-citationHartkoorn, R. C., Uplekar, S., & Cole, S. T. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00037-14 · Cited by 489
Analysis of the Phthiocerol Dimycocerosate Locus ofMycobacterium tuberculosis
Camacho, L. R., Constant, P., Raynaud, C., Lanéelle, M.-A., Triccas, J. A., Gicquel, B., Daffé, M., & Guilhot, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100662200 · Cited by 382
Diacon, A. H., Donald, P. R., Pym, A., Grobusch, M., Patientia, R. F., Mahanyele, R., Bantubani, N., Narasimooloo, R., De Marez, T., van Heeswijk, R., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06126-11 · Cited by 377
Self-citationContribution of the Mycobacterium tuberculosis MmpL Protein Family to Virulence and Drug Resistance
Domenech, P., Reed, M. B., & Barry, C. E. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3492-3501.2005 · Cited by 361
Koul, A., Vranckx, L., Dhar, N., Göhlmann, H. W. H., Özdemir, E., Neefs, J.-M., Schulz, M., Lu, P., Mørtz, E., McKinney, J. D., et al. (2014) · Nature Communications · doi:10.1038/ncomms4369 · Cited by 293
Self-citationIdentification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis
Ioerger, T. R., O’Malley, T., Liao, R., Guinn, K. M., Hickey, M. J., Mohaideen, N., Murphy, K. C., Boshoff, H. I. M., Mizrahi, V., Rubin, E. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075245 · Cited by 241
Huitric, E., Verhasselt, P., Koul, A., Andries, K., Hoffner, S., & Andersson, D. I. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01611-09 · Cited by 215
Self-citationEfflux as a mechanism for drug resistance in Mycobacterium tuberculosis: Table 1
da Silva, P. E. A., Von Groll, A., Martin, A., & Palomino, J. C. (2011) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2011.00831.x · Cited by 199
Schmalstieg, A. M., Srivastava, S., Belkaya, S., Deshpande, D., Meek, C., Leff, R., van Oers, N. S. C., & Gumbo, T. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05546-11 · Cited by 195
Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis
Gupta, S., Cohen, K. A., Winglee, K., Maiga, M., Diarra, B., & Bishai, W. R. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01462-13 · Cited by 186
Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5–MmpL5 efflux system
Milano, A., Pasca, M. R., Provvedi, R., Lucarelli, A. P., Manina, G., Luisa de Jesus Lopes Ribeiro, A., Manganelli, R., & Riccardi, G. (2009) · Tuberculosis · doi:10.1016/j.tube.2008.08.003 · Cited by 181
Acceleration of Tuberculosis Treatment by Adjunctive Therapy with Verapamil as an Efflux Inhibitor
Gupta, S., Tyagi, S., Almeida, D. V., Maiga, M. C., Ammerman, N. C., & Bishai, W. R. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201304-0650oc · Cited by 171
Approval of Novel TB Drug Celebrated—With Restraint
Cohen, J. (2013) · Science · doi:10.1126/science.339.6116.130 · Cited by 166
Louw, G. E., Warren, R. M., Gey van Pittius, N. C., Leon, R., Jimenez, A., Hernandez-Pando, R., McEvoy, C. R. E., Grobbelaar, M., Murray, M., van Helden, P. D., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1924oc · Cited by 166
de Steenwinkel, J. E. M., de Knegt, G. J., ten Kate, M. T., van Belkum, A., Verbrugh, H. A., Kremer, K., van Soolingen, D., & Bakker-Woudenberg, I. A. J. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq374 · Cited by 164
Lamichhane, G., Tyagi, S. K., & Bishai, W. R. (2005) · Infection and Immunity · doi:10.1128/iai.73.4.2533-2540.2005 · Cited by 158
Williams, K. N., Minkowski, A., Amoabeng, O., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00384-12 · Cited by 156
Segala, E., Sougakoff, W., Chauffour, A., Jarlier, V., & Petrella, S. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06154-11 · Cited by 133
Analysis of the Genome of Mycobacterium tuberculosis H37Rv
Cole, S. T., & Barrell, B. G. (1998) · Novartis Foundation symposium · doi:10.1002/0470846526.ch12 · Cited by 107
Dasgupta, S. K., Jain, S., Kaushal, D., & Tyagi, A. K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8724 · Cited by 58
Cited by
Multidrug efflux pumps: structure, function and regulation
Du, D., Wang-Kan, X., Neuberger, A., van Veen, H. W., Pos, K. M., Piddock, L. J. V., & Luisi, B. F. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0048-6 · Cited by 1,055
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Dookie, N., Rambaran, S., Padayatchi, N., Mahomed, S., & Naidoo, K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx506 · Cited by 346
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis
Pym, A. S., Diacon, A. H., Tang, S.-J., Conradie, F., Danilovits, M., Chuchottaworn, C., Vasilyeva, I., Andries, K., Bakare, N., De Marez, T., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00724-2015 · Cited by 333
Self-citationA macroevolution-inspired approach to reveal novel antibiotic resistance mechanisms
Subtil, F. T., Machado, T. F., Douglas, H., Kirkpatrick, J. M., Skehel, M., Garza-Garcia, A., & de Carvalho, L. P. S. (2026) · eLife · doi:10.7554/elife.101940 · Cited by 1
Metadata
- Authors
- Andries, K., Villellas, C., Coeck, N., Thys, K., Gevers, T., Vranckx, L., Lounis, N., de Jong, B. C., & Koul, A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-10
- Volume
- 9
- Issue
- 7
- Pages
- e102135
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2055092907
- Cited by
- 439
- References
- 24
- FWCI
- 21.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.